Adverse drug events in hospitalized patients

A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.

European journal of clinical pharmacology·2021

Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients.

Expert opinion on drug safety·2017

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Leukemia·2016

A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction.

European journal of clinical pharmacology·2016

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Leukemia·2016

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

JAMA·2026

Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

JAMA·2026

RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season.

JAMA·2026

Indications for the treatment of primary hyperparathyroidism.

Journal of visceral surgery·2026

Sodium valproate at concentrations bracketing estimated seminal plasma levels impairs human sperm function in vitro through oxidative stress and mitochondrial dysfunction.

Toxicology·2026

Pharmacokinetics of repeated, high-dose fentanyl administration in rats.

Drug metabolism and disposition: the biological fate of chemicals·2026

A landscape analysis of Japanese tolerability assessments in oncology drug development.

Cancer treatment and research communications·2026

Opioid and Stimulant Coprescriptions among South Carolina Residents.

Southern medical journal·2026

Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease.

JAMA network open·2026

Related Experiment Videos

Adverse drug events in hospitalized patients

Related Concept Videos

A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.

Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season.

Indications for the treatment of primary hyperparathyroidism.

Sodium valproate at concentrations bracketing estimated seminal plasma levels impairs human sperm function in vitro through oxidative stress and mitochondrial dysfunction.

Pharmacokinetics of repeated, high-dose fentanyl administration in rats.

A landscape analysis of Japanese tolerability assessments in oncology drug development.

Opioid and Stimulant Coprescriptions among South Carolina Residents.

Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease.

Related Experiment Videos

Adverse drug events in hospitalized patients

Related Concept Videos

Related Articles